Cefizoxime: Difference between revisions
(Text replacement - "==References== <references/>" to "==References== <references/>") |
ClaireLewis (talk | contribs) No edit summary |
||
Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: 3rd generation cephalosporin (Discontinued) | *Type: 3rd generation [[cephalosporin]] (Discontinued) | ||
*Dosage Forms: powder for injection | *Dosage Forms: powder for injection | ||
*Dosage Strengths: 500mg, 1g, 2g, 10g | *Dosage Strengths: 500mg, 1g, 2g, 10g | ||
Line 163: | Line 163: | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:ID]] |
Latest revision as of 21:50, 19 September 2019
General
- Type: 3rd generation cephalosporin (Discontinued)
- Dosage Forms: powder for injection
- Dosage Strengths: 500mg, 1g, 2g, 10g
- Routes of Administration: IV, IM
- Common Trade Names: Cefizox
Adult Dosing
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
Common
Pharmacology
- Half-life: 1.6 - 1.9/hr
- Metabolism:
- Excretion: urine, as unchanged drug
- Mechanism of Action: arrests bacterial growth by binding to one or more penicillin binding proteins
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014